Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof

A compound of Formula (II),

• or a pharmaceutically acceptable salt thereof,
• wherein:
• R1 is C1-6 alkyl optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, and C1-3 alkoxy;
• R3 is hydrogen, halogen, C1-6 alkyl, C3-6 cycloalkyl, —O—R3A, or —N(R3A)2, wherein the C1-6 alkyl is optionally substituted with 1 to 3 substituents independently selected from C1-3 alkoxy and halogen, and wherein each R3A is independently C1-3 alkyl optionally substituted with 1 to 3 halogens;
• each R4 is independently deuterium, halogen, C1-6 alkyl, C3-10 cycloalkyl, or C1-3 alkoxy, wherein the C1.6 alkyl or C3-10 cycloalkyl, is optionally substituted with 1 to 3 halogens;
• n is 0, 1 or 2;
• R5 is C1-6 alkyl optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, C1-3 alkoxy, —C(O)N(R1A), and —N(R1A)2, wherein each R1A is independently —H, C1-6 alkyl, or C3-10 cycloalkyl;
• or
• R5 is C3-6 cycloalkyl or 3 to 6 membered heterocyclyl having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the cycloalkyl or heterocyclyl are optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, C1-3 alkyl and C1-3 alkoxy;
• Y is hydrogen or C1-6 alkyl optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, C1-3 alkynyl, C1-3 alkoxy, and —C(O)NH—Ry, wherein Ry is C1-3 alkyl;
• and
• Z is 5 to 12 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, C1-3 alkyl, C1-3 alkenyl, C1-3 alkoxy, and C3-6 cycloalkyl, wherein the C1-3 alkyl is optionally substituted with 1 to 3 substituents selected from C1-3 alkoxy and halogen.